<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study compared <z:chebi fb="0" ids="40303">lovastatin</z:chebi> and <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> therapy for effects on <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> levels in 22 normolipidemic patients with reduced <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>Most patients had <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A randomized, crossover design consisted of two drug phases (<z:chebi fb="0" ids="40303">lovastatin</z:chebi> and <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi>) alternating with placebo </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="40303">Lovastatin</z:chebi> reduced total and <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B levels by 28%, 34%, and 24%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>These were unaffected by <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Both drugs reduced <z:chebi fb="0" ids="39027">very low-density lipoprotein</z:chebi> and intermediate-density <z:chebi fb="0" ids="50404">lipoprotein cholesterol</z:chebi> levels by 30% to 40% </plain></SENT>
<SENT sid="6" pm="."><plain>Both caused small but significant increases in <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, but not in <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi> A-I or A-II </plain></SENT>
<SENT sid="7" pm="."><plain>Both significantly lowered ratios of total (and <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi>) cholesterol-to-<z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, but <z:chebi fb="0" ids="40303">lovastatin</z:chebi> more than <z:chebi fb="0" ids="5296">gemfibrozil</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, for normolipidemic patients with low levels of <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, neither drug markedly raised <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> levels, but <z:chebi fb="0" ids="40303">lovastatin</z:chebi> produced the better overall change in <z:chebi fb="0" ids="50404">lipoprotein cholesterol</z:chebi> and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B levels </plain></SENT>
</text></document>